Is Corbus Pharmaceuticals Stock a Good Investment?
Corbus Pharmaceuticals Investment Advice | CRBP |
- Examine Corbus Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Corbus Pharmaceuticals' leadership team and their track record. Good management can help Corbus Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Corbus Pharmaceuticals' business and its evolving consumer preferences.
- Compare Corbus Pharmaceuticals' performance and market position to its competitors. Analyze how Corbus Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Corbus Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Corbus Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Corbus Pharmaceuticals Holding stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Corbus Pharmaceuticals Holding is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Corbus Pharmaceuticals Stock
Researching Corbus Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.41. Some equities with similar Price to Book (P/B) outperform the market in the long run. Corbus Pharmaceuticals recorded a loss per share of 4.71. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 14th of February 2023.
To determine if Corbus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Corbus Pharmaceuticals' research are outlined below:
| Corbus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corbus Pharmaceuticals has high historical volatility and very poor performance | |
| Corbus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (44.6 M) with loss before overhead, payroll, taxes, and interest of (16.14 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Corbus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference |
Corbus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Corbus Pharmaceuticals Holding. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Corbus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Corbus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Corbus Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2015-08-13 | 2015-06-30 | -0.11 | -0.0953 | 0.0147 | 13 | ||
2024-11-05 | 2024-09-30 | -0.95 | -1.15 | -0.2 | 21 | ||
2024-05-07 | 2024-03-31 | -1.09 | -0.83 | 0.26 | 23 | ||
2024-08-06 | 2024-06-30 | -1.19 | -0.9 | 0.29 | 24 | ||
2022-11-08 | 2022-09-30 | -1.65 | -2.1 | -0.45 | 27 | ||
2023-03-07 | 2022-12-31 | -2.1 | -2.61 | -0.51 | 24 | ||
2016-11-10 | 2016-09-30 | -3.07 | -3.6 | -0.53 | 17 | ||
2024-03-12 | 2023-12-31 | -2.36 | -1.81 | 0.55 | 23 |
Know Corbus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corbus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corbus Pharmaceuticals Holding backward and forwards among themselves. Corbus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Corbus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 249.8 K | Woodline Partners Lp | 2024-06-30 | 249.3 K | Millennium Management Llc | 2024-06-30 | 241.6 K | Assenagon Asset Management Sa | 2024-09-30 | 221.2 K | Hhg Plc | 2024-06-30 | 203.3 K | Altium Capital Management, Lp | 2024-09-30 | 195 K | Silverarc Capital Management, Llc | 2024-06-30 | 172.5 K | Vivo Capital, Llc | 2024-09-30 | 166.8 K | Ghost Tree Capital, Llc | 2024-09-30 | 160 K | Cormorant Asset Management, Llc | 2024-09-30 | 2.4 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.1 M |
Corbus Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 212.78 M.Market Cap |
|
Corbus Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.58) | (1.66) | |
| Return On Capital Employed | 12.45 | 13.07 | |
| Return On Assets | (1.58) | (1.66) | |
| Return On Equity | 6.46 | 6.78 |
Determining Corbus Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Corbus Pharmaceuticals is a good buy. For example, gross profit margin measures Corbus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Corbus Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Corbus Pharmaceuticals' management efficiency
Corbus Pharmaceuticals has return on total asset (ROA) of (0.2882) % which means that it has lost $0.2882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5132) %, meaning that it created substantial loss on money invested by shareholders. Corbus Pharmaceuticals' management efficiency ratios could be used to measure how well Corbus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Corbus Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 11/25/2024, Return On Equity is likely to grow to 6.78, while Return On Tangible Assets are likely to drop (1.66). As of 11/25/2024, Liabilities And Stockholders Equity is likely to grow to about 50.5 M, while Total Current Liabilities is likely to drop slightly above 16.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.60) | (1.52) | |
| Net Current Asset Value | (178.54) | (187.47) | |
| Tangible Asset Value | (178.54) | (187.47) | |
| Tangible Book Value Per Share | (1.60) | (1.52) | |
| Enterprise Value Over EBITDA | (0.74) | (0.78) | |
| Price Book Value Ratio | (3.79) | (3.60) | |
| Enterprise Value Multiple | (0.74) | (0.78) | |
| Price Fair Value | (3.79) | (3.60) | |
| Enterprise Value | 19.8 M | 18.8 M |
Corbus Pharmaceuticals' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 2.565 |
Basic technical analysis of Corbus Stock
As of the 25th of November, Corbus Pharmaceuticals shows the Standard Deviation of 8.76, risk adjusted performance of (0.1), and Mean Deviation of 4.03. Corbus Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Corbus Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corbus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corbus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corbus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corbus Pharmaceuticals' Outstanding Corporate Bonds
Corbus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Corbus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Corbus bonds can be classified according to their maturity, which is the date when Corbus Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Corbus Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Corbus Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.82) | |||
| Mean Deviation | 4.03 | |||
| Coefficient Of Variation | (710.02) | |||
| Standard Deviation | 8.76 | |||
| Variance | 76.75 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.43) | |||
| Total Risk Alpha | (2.62) | |||
| Treynor Ratio | (0.83) | |||
| Maximum Drawdown | 70.46 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 6.77 | |||
| Skewness | (5.16) | |||
| Kurtosis | 36.99 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.82) | |||
| Mean Deviation | 4.03 | |||
| Coefficient Of Variation | (710.02) | |||
| Standard Deviation | 8.76 | |||
| Variance | 76.75 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.43) | |||
| Total Risk Alpha | (2.62) | |||
| Treynor Ratio | (0.83) | |||
| Maximum Drawdown | 70.46 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 6.77 | |||
| Skewness | (5.16) | |||
| Kurtosis | 36.99 |
Consider Corbus Pharmaceuticals' intraday indicators
Corbus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Corbus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Corbus Pharmaceuticals Corporate Filings
8K | 15th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 22nd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Corbus Stock media impact
Far too much social signal, news, headlines, and media speculation about Corbus Pharmaceuticals that are available to investors today. That information is available publicly through Corbus media outlets and privately through word of mouth or via Corbus internal channels. However, regardless of the origin, that massive amount of Corbus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Corbus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Corbus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Corbus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Corbus Pharmaceuticals alpha.
Corbus Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Corbus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Corbus Pharmaceuticals Corporate Management
| MD MA | Chief Officer | Profile | |
| Christina Bertsch | Head Resources | Profile | |
| CPA MBA | Chief Officer | Profile | |
| Rachael Brake | Chief Officer | Profile | |
| Lindsey Smith | Head Advocacy | Profile |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.